
Sign up to save your podcasts
Or


Are you still calling it "juvenile diabetes"? You might be making a dangerous medical assumption! The groundbreaking 2026 JAMA Review reveals a startling demographic shift: the median age for a Type 1 Diabetes diagnosis in the US is now 24 years old. In this deep dive, Dr. Kai and Dr. Mai unpack the hidden symptoms of Type 1 diabetes, explaining why so many adults are misdiagnosed with Type 2 when they actually have LADA. We explore the critical role of the C-peptide test, break down the 3 stages of Type 1 diabetes , and highlight the latest tech changing diabetes care—like Automated Insulin Delivery (AID) systems. Plus, we cover the revolutionary breakthrough drug Teplizumab that is actively delaying clinical symptoms, and warn about the silent threat of euglycemic DKA. Whether you are a clinician trying to stop missing the signs or a patient wanting to know what the 2026 JAMA Review actually says, this episode is essential listening!
Reference: Jacobsen LM, Schatz DA. Type 1 Diabetes: A Review. JAMA. Published online February 16, 2026. doi:10.1001/jama.2026.0048
Watch on YouTube with subtitles: https://www.youtube.com/@whatthestudysays
Podcast: https://podcasts.apple.com/tw/podcast/what-the-study-says/id1814559387
FLink: https://open.firstory.me/user/cmao5odis0eyf01w36mahd8ub/platforms
Tell us what you think:
By Dr. StudyAre you still calling it "juvenile diabetes"? You might be making a dangerous medical assumption! The groundbreaking 2026 JAMA Review reveals a startling demographic shift: the median age for a Type 1 Diabetes diagnosis in the US is now 24 years old. In this deep dive, Dr. Kai and Dr. Mai unpack the hidden symptoms of Type 1 diabetes, explaining why so many adults are misdiagnosed with Type 2 when they actually have LADA. We explore the critical role of the C-peptide test, break down the 3 stages of Type 1 diabetes , and highlight the latest tech changing diabetes care—like Automated Insulin Delivery (AID) systems. Plus, we cover the revolutionary breakthrough drug Teplizumab that is actively delaying clinical symptoms, and warn about the silent threat of euglycemic DKA. Whether you are a clinician trying to stop missing the signs or a patient wanting to know what the 2026 JAMA Review actually says, this episode is essential listening!
Reference: Jacobsen LM, Schatz DA. Type 1 Diabetes: A Review. JAMA. Published online February 16, 2026. doi:10.1001/jama.2026.0048
Watch on YouTube with subtitles: https://www.youtube.com/@whatthestudysays
Podcast: https://podcasts.apple.com/tw/podcast/what-the-study-says/id1814559387
FLink: https://open.firstory.me/user/cmao5odis0eyf01w36mahd8ub/platforms
Tell us what you think: